// App-Quantinova.ai

BSH19‐PO‐100 : Treatment outcomes of T and natural‐killer/T‐cell lymphoma with ifosfamide, carboplatin, etoposide (ICE) chemotherapy

Researchers

Presenter

  • T. Tay

Principal Investigators

  • L.P. Khoo

  • C. Lim

  • A.Z.K. Goh

  • Y.S. Lee

  • X. Liu

  • M. Tao

  • R. Quek

  • M. Farid

  • E.Y.L. Poon

  • J.Y. Chan

  • Y.T. Goh

  • D. Tan

  • C.P. Diong

  • N. Grigoropoulos

  • C. Nagarajan

  • M. Poon

  • S.T. Lim

  • T. Tang

Medical Centers

  • Manchester Medical School, University of Manchester, Manchester, United Kingdom

  • Division of Medical Oncology, National Cancer Centre, Singapore

  • Department of Haematology-Oncology, National University Cancer Institute, Singapore, Singapore, Singapore

  • Raffles Cancer Center, Singapore, Singapore

Locations

  • United Kingdom

  • Singapore

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Peripheral T-cell lymphoma

  • Lymphomas

  • Solid malignancies

Biomarkers

  • DNA Damage Inducible Transcript 3

Drug/Treatment

  • Carboplatin

  • Ifosfamide

  • Etoposide

  • Etoposide phosphate

  • PR-26

Outcome

  • N/A

Study Design

  • Cohort

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved